Rocket Pharmaceuticals, Inc. (RCKT)

The litigation focuses on the propriety of Rocket Pharmaceutical’s disclosures about the trial protocol being implemented in the RP-A501 Phase 2 trial.

More specifically, the complaint alleges that Rocket Pharmaceuticals made materially false and misleading statements while failing to disclose to investors: (1) the true state of RP-A501’s safety and clinical trial protocol; (2) that the company knew Serious Adverse Events (“SAEs”), including patient’s deaths, were at risk; and (3) that the company amended the trials protocol to introduce a novel immunomodulatory agent to the pretreatment regimen.

Investors learned the truth on May 27, 2025, when the company revealed that the FDA put a clinical hold on its Phase 2 study after a patient suffered a SAE and ultimately died. During the May 27, 2025 update call, in response to analysts’ questions, management revealed that the company amended the trial protocol “several months ago[.]” The analysts were seemingly unaware of the company’s amendments before this update call.

This news drove the price of Rocket Pharmaceutical’s shares crashing $3.94 (-62%) the same day.

FREQUENTLY ASKED QUESTIONS ABOUT THE CASE

What is the RCKT investigation about?

We are investigating claims that Rocket Pharmaceuticals may have misled investors about its Phase 2 protocol and whether it secretly amended it without first notifying the FDA and investors.

WHAT SHOULD I DO?

I worked at RCKT. What should I do?

If you were an employee of RCKT, you may have valuable information that could be relevant to the investigation. Hagens Berman is one of the nation’s top whistleblower law firms, and has successfully represented many individuals who come forward with information regarding corporate malfeasance. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, contact Reed Kathrein at 844-916-0895 or [email protected].

There are multiple law firms participating, do I need to contact all of them?

No, you do not need to contact all participating law firms. Generally, class-action investigations and lawsuits are consolidated into a single case to streamline the legal process, and attorneys from only a few law firms are selected to serve in a leadership role on the consolidated case. Hagens Berman has a proven track record of being appointed to leadership roles in complex, multidistrict litigation regarding investor fraud and other consumer rights issues, and your claim will be handled by attorneys who have helped secure approximately $325 billion in class-action settlements on behalf of individuals who have suffered due to corporate malfeasance and the wrongdoing of other powerful institutions.

AM I ELIGIBLE?

What is the threshold amount to be eligible? What are “substantial” losses?

The threshold amount and the definition of "substantial" losses may vary depending on a number of factors specific to the case, including the size of the company, market cap, shares outstanding and who holds them and the damages alleged by the fraud. In general, to be eligible to participate in a class-action lawsuit, you must be able to demonstrate that you suffered financial losses as a result of the alleged wrongdoing and that your losses meet the criteria set by the court or law firm. Fill out the form and submit your losses.

CAN I PARTICIPATE?

Am I affected? What do I need to do to participate?

If you were an investor in RCKT, you may be affected and eligible to participate in the case. To determine your eligibility and potential involvement, fill out the form and submit your losses.

Can any RCKT investor participate?

In most class-action investigations and cases, any investor who meets the eligibility criteria, including purchasing the shares during the relevant period, can participate, regardless of the size of their investment. Fill out the form to find out your rights.

I bought on a non-U.S. Exchange. Can I participate?

No. This investigation only covers shares bought on a U.S. exchange, i.e. NASDAQ or NYSE. Fill out the form to find out your rights.

Am I included if I still hold my shares, or do I need to sell to participate?

Participation is based on purchasing shares during the relevant period, rather than your current holdings. Accordingly, you do not need to sell to participate. Fill out the form to find out your rights.